Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Hendrik Scholl sold 2,000 shares of the firm's stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $165.99, for a total transaction of $331,980.00. Following the completion of the transaction, the insider owned 12,500 shares of the company's stock, valued at approximately $2,074,875. The trade was a 13.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Hendrik Peter Scholl also recently made the following trade(s):
- On Thursday, October 1st, Hendrik Scholl sold 500 shares of Belite Bio stock. The shares were sold at an average price of $165.32, for a total transaction of $82,660.00.
Belite Bio Stock Down 1.1%
Shares of BLTE stock traded down $1.79 during trading hours on Monday, reaching $162.56. 191,275 shares of the stock traded hands, compared to its average volume of 173,816. The firm has a market capitalization of $6.55 billion, a PE ratio of -59.55 and a beta of -1.19. Belite Bio, Inc. Sponsored ADR has a 1-year low of $105.88 and a 1-year high of $200.00. The business has a fifty day moving average price of $160.26 and a 200 day moving average price of $160.22.
Belite Bio (NASDAQ:BLTE - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.19. Research analysts expect that Belite Bio, Inc. Sponsored ADR will post -3.08 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
BLTE has been the subject of several recent analyst reports. Jefferies Financial Group reaffirmed a "hold" rating on shares of Belite Bio in a research report on Wednesday, September 9th. Zacks Research lowered Belite Bio from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 18th. UBS Group reissued a "buy" rating on shares of Belite Bio in a research note on Thursday, September 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of Belite Bio in a research report on Friday, October 2nd. Finally, Canaccord Genuity Group lifted their target price on Belite Bio from $303.00 to $314.00 and gave the company a "buy" rating in a research note on Monday. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $226.91.
View Our Latest Research Report on Belite Bio
Institutional Investors Weigh In On Belite Bio
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BLTE. Vise Technologies Inc. purchased a new position in shares of Belite Bio during the 3rd quarter valued at $217,000. GAMMA Investing LLC raised its holdings in shares of Belite Bio by 5.0% during the third quarter. GAMMA Investing LLC now owns 1,771 shares of the company's stock worth $301,000 after acquiring an additional 85 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Belite Bio by 7.9% during the first quarter. Royal Bank of Canada now owns 2,257 shares of the company's stock worth $360,000 after acquiring an additional 165 shares in the last quarter. Engineers Gate Manager LP boosted its position in Belite Bio by 11.4% during the second quarter. Engineers Gate Manager LP now owns 2,773 shares of the company's stock valued at $427,000 after purchasing an additional 284 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in Belite Bio by 104.0% during the first quarter. Bank of America Corp DE now owns 3,778 shares of the company's stock valued at $602,000 after purchasing an additional 1,926 shares during the last quarter. Hedge funds and other institutional investors own 0.53% of the company's stock.
Belite Bio Company Profile
(
Get Free Report)
Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Belite Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Belite Bio wasn't on the list.
While Belite Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.